Adding Liraglutide to Insulin in Type 1 Diabetes: What 5 Trials Show

Systematic review and meta-analysis of 5 randomized controlled trials (≥12 weeks duration) comparing liraglutide vs placebo as add-on to insulin in type 1 diabetes patients. Searched major databases and grey literature through October 2018. Reported per PRISMA guidelines. Assessed efficacy (HbA1c, weight, insulin dose) and safety (hypoglycemia, GI events, ketoacidosis) endpoints.

Type 1 diabetes treatment has relied almost exclusively on insulin, with limited options for adjunct therapy. GLP-1 agonists like liraglutide are widely used in type 2 diabetes but their role in type 1 is less established. This meta-analysis provides the most comprehensive evidence to date that liraglutide can meaningfully reduce weight and insulin requirements in T1D patients, though the blood sugar benefit is modest and GI side effects are significant.

While GLP-1 agonists have transformed type 2 diabetes and obesity treatment, their role in type 1 diabetes remains niche. This meta-analysis suggests liraglutide's main benefit in T1D is weight loss and insulin-sparing rather than blood sugar control — a different value proposition than in T2D. The FDA has not approved any GLP-1 for T1D, and the high GI side effect burden makes patient selection important.

Only 5 trials met inclusion criteria, limiting the ability to detect rarer adverse events. Follow-up durations were relatively short (≥12 weeks), so long-term safety and efficacy in T1D remain uncertain. The modest HbA1c reduction (-0.24%) may not justify the high rate of GI side effects for all patients. Individual patient factors that predict who benefits most were not explored.